Read Occupational Therapist Samar Muslemani’s Early Career Blog

Read the latest early career blog post, from NMD4C member Samar Muslemani, OT, M.Sc.

Full blog available here!


Excerpt:

“Occupational therapy is where science, creativity, and compassion collide”

This is a quote from Jessica Kensky, a survivor of the 2013 Boston Marathon bombing and keynote speaker at the 2016 American Occupational Therapy Association welcome ceremony. To me, this quote represents exactly what I love about my profession. Pursuing a PhD allows me to develop these three elements even further.


Samar Muslemani holds a Master’s Degree in Occupational Therapy and has been practicing in Saguenay, Québec since 2018. She is a doctoral student with the University of Sherbrooke. She aims to better understand the functional impacts of cognitive impairments in people living with myotonic dystrophy type 1. She completed a research Master’s Degree in Health Sciences in August 2021. Her project aimed to document independence and social participation of adults living with childhood phenotype of DM1. She received a bursary of the Fonds de recherche du Québec – Santé (FRQS), and has assessed patients both in Canada and France as part of her research project. Native from Saguenay-Lac-Saint-Jean region, she is interested in offering more support to patients and families with neuromuscular diseases (NMD) in her native region and internationally. Both in her research and clinical practice, she has worked with various NMDs, such as recessive spastic ataxia of Charlevoix-Saguenay, oculopharyngeal muscular dystrophy and Charcot-Marie-Tooth diseases. She is the first author of a practical guideline to support occupational therapists in addressing sexuality with their NMD patients. 

Within the NMD4C, Samar supports the Knowledge Translation team through developing knowledge and skills, defining barriers, and reducing the knowledge-to-action gap by developing various tools including clinical practice guidelines in the NMD field. 

Samar Muslemani EC Blog

Read next...

06 - 2026 Basic Research Summer School - EN

NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!

From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages. 

New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada

We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.